MINOCIN by Bausch + Lomb is clinical pharmacology following a single dose of minocin 200 mg administered intravenously to 10 healthy male subjects, serum concentrations of minocycline ranged from 2. Approved for infections caused by the following gram-negative bacteria, infections caused by the following gram-positive bacteria, the treatment of the following infections due to susceptible isolates of the designated bacteria: rocky mountain spotted fever and 5 more indications. First approved in 1972.
Drug data last refreshed 5h ago · AI intelligence enriched 1w ago
MINOCIN (minocycline) is a tetracycline-class bacteriostatic antibiotic approved in 1972 that inhibits bacterial protein synthesis by binding to the ribosome. It treats a broad spectrum of gram-positive and gram-negative bacterial infections, rickettsial diseases (Rocky Mountain spotted fever, Q fever, typhus), and atypical organisms including Chlamydia and Mycoplasma. Administered as an oral suspension, it achieves serum half-lives of 15–23 hours in healthy subjects, with prolonged elimination in hepatic and renal impairment.
LOE-stage product with 30% competitive pressure suggests defensive brand management focus and potential consolidation of support teams.
CLINICAL PHARMACOLOGY Following a single dose of Minocin 200 mg administered intravenously to 10 healthy male subjects, serum concentrations of minocycline ranged from 2.52 to 6.63 mcg/mL (average 4.18 mcg/mL) at the end of infusion and 0.82 to 2.64 mcg/mL (average 1.38 mcg/mL) after 12 hours. In a…
Worked on MINOCIN at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on MINOCIN as a Bausch + Lomb legacy asset offers limited growth but stable, specialized expertise in antibiotic portfolio management, generic defense, and niche market maintenance. Roles focus on operational efficiency, compliance, and formulary retention rather than launch or expansion.